Key result
Astragaloside IV shows antiarrhythmic potential by mitigating ischemia-reperfusion injury, reducing fibrosis, and restoring ion homeostasis.
Why the study?
Arrhythmia incidence and mortality remain high with drug-related adverse effects posing challenges, and comprehensive reviews of astragaloside IV's specific mechanisms and clinical applications are scarce.
Design
Comprehensive review
Authors
Loading...
Should not change arrhythmia practice; hypothesis-generating and leaves open need for randomized trials.
Astragaloside IV demonstrates multi-targeted anti-arrhythmic potential through antioxidant, anti-inflammatory, anti-fibrotic, and ion channel regulatory mechanisms.
Chen et al. (2025) conducted a review in Arrhythmia. Astragaloside IV was evaluated. Astragaloside IV exhibits therapeutic potential for arrhythmia by mitigating ischemia-reperfusion injury, reducing myocardial fibrosis, and restoring ion channel homeostasis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: